EARLY TERMINATIONS GRANTED OCTOBER 1, 2018 THRU OCTOBER 31, 2018—Continued

20190099	G	Gerald W. Schwartz; Impakt Holdings, LLC; Gerald W. Schwartz.
20190100	G	The E.W. Scripps Company; Vector Capital IV International, L.P.; The E.W. Scripps Company.
20190102	G	Matterhorn Parent, LLC; Greencore Group plc; Matterhorn Parent, LLC.
20190110	G	Snow Phipps III, L.P.; James M. Traube; Snow Phipps III, L.P.
20190111	G	Snow Phipps III, L.P.; Mario Gleijeses; Snow Phipps III, L.P.
20190114	G	Robert L. Moody, Sr.; Charles N. Sharpe trust Dated August 28,1987; Robert L. Moody, Sr.
20190118	G	Hildred Holdings LLC; GlaxoSmithKline, plc; Hildred Holdings LLC.
		10/29/2018
20190083	G	CVC Capital Partners Asia Pacific IV L.P.; UnitedLex BPO Private Limited; CVC Capital Partners Asia Pacific IV L.P.
20190126	G	Audax Private Equity Fund V–A, L.P.; Tailwind Capital Partners II, L.P.; Audax Private Equity Fund V–A, L.P.
20190128	G	Macquarie Infrastructure Partners IV, L.P.; Wheelabrator Technologies, Inc.; Macquarie Infrastructure Partners IV, L.P.
		10/30/2018
20190085	G	Howard W. Lutnick; Nasdaq, Inc.; Howard W. Lutnick.
20190117	G	SP Plus Corporation; Craig C. Mateer; SP Plus Corporation.
20190119	G	HGGC Fund III–A, L.P.; General Atlantic Partners 100, L.P.; HGGC Fund III–A, L.P.
20190127	G	Apollo Infra Equity US Fund, L.P. (Infra Equity); General Elecric Company; Apollo Infra Equity US Fund, L.P. (Infra Equity).
20190131	G	IRI Parent, L.P.; New Mountain Partners III, L.P.; IRI Parent, L.P.
		10/31/2018
20190075	G	Pamlico Capital III, L.P.; National Restaurant Association; Pamlico Capital III, L.P.
20190103	G	Precision Drilling Corporation; Trinidad Drilling Ltd.; Precision Drilling Corporation.
20190120	G	Blackstone Energy Partners II Q L.P.; ISQ Global Infrastructure Fund II, L.P; Blackstone Energy Partners II Q L.P.
20190136	G	Sentinel Management Holdings, LLC; LCP VIII (AIV I), L.P.; Sentinel Management Holdings, LLC.

FOR FURTHER INFORMATION CONTACT: Theresa Kingsberry, Program Support Specialist, Federal Trade Commission Premerger Notification Office, Bureau of Competition, Room CC–5301, Washington, DC 20024, (202) 326–3100.

By direction of the Commission.

April J. Tabor,

Acting Secretary.

[FR Doc. 2019–07326 Filed 4–11–19; 8:45 am]

BILLING CODE 6750–01–P

DEPARTMENT OF DEFENSE

GENERAL SERVICES ADMINISTRATION

NATIONAL AERONAUTICS AND SPACE ADMINISTRATION

[OMB Control No. 9000–0083; Docket No. 2019–0003; Sequence No. 3]

Information Collection; Qualification Requirements

AGENCY: Department of Defense (DOD), General Services Administration (GSA), and National Aeronautics and Space Administration (NASA).

ACTION: Notice of reinstatement request for an information collection requirement regarding an existing OMB clearance.

SUMMARY: Under the provisions of the Paperwork Reduction Act, the Regulatory Secretariat Division will be submitting to the Office of Management and Budget (OMB) a request to review and approve an extension of a previously approved information collection requirement concerning Qualification Requirements.

DATES: Submit comments on or before June 11, 2019.

ADDRESSES: The FAR Council invites interested persons to submit comments on this collection by either of the following methods:

- *Federal eRulemaking Portal:* This website provides the ability to type short comments directly into the comment field or attach a file for lengthier comments. Go to *http://www.regulations.gov* and follow the instructions on the site.
- *Mail:* General Services Administration, Regulatory Secretariat Division (MVCB), 1800 F Street NW, Washington, DC 20405. ATTN: Ms. Flowers/IC 9000–0083, Qualification Requirements.

Instructions: All items submitted must cite Information Collection 9000–0083, Qualification Requirements. Comments received generally will be posted without change to *http://www.regulations.gov,* including any personal and/or business confidential information provided. To confirm receipt of your comment(s), please check *www.regulations.gov,* approximately two to three days after submission to verify posting (except allow 30 days for posting of comments submitted by mail). This information collection is pending at the FAR Council. The Council will submit it to OMB within 60 days from the date of this notice.

FOR FURTHER INFORMATION CONTACT: Ms. Camara Francis, Procurement Analyst, Office of Governmentwide Acquisition Policy, GSA, 202–550–0935, or *camara.francis@gsa.gov.*

SUPPLEMENTARY INFORMATION:

A. Solicitation of Public Comment

Written comments and suggestions from the public should address one or more of the following four points:

(1) Evaluate whether the collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;

(2) Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;

(3) Enhance the quality, utility, and clarity of the information to be collected; and

(4) Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, *e.g.,* permitting electronic submission of responses.

B. Purpose

FAR subpart 9.2 and the associated clause at FAR 52.209–1, implement the statutory requirements of 10 U.S.C. 2319 and 41 U.S.C. 3311, which allow an agency to establish a qualification requirement for testing or other quality assurance demonstration that must be completed by an offeror before award of a contract. Under the qualification requirements, an end item, or a component thereof, may be required to be prequalified.

The clause at FAR 52.209–1, Qualification Requirements, requires offerors who have met the qualification requirements to identify the offeror's name, the manufacturer's name, source's name, the item name, service identification, and test number (to the extent known). This eliminates the need for an offeror to provide new information when the offeror, manufacturer, source, product or service covered by qualification requirement has already met the standards specified by an agency in a solicitation.

The contracting officer uses the information to determine eligibility for award when the clause at 52.209–1 is included in the solicitation. Alternatively, items not yet listed may be considered for award upon the submission of evidence of qualification with the offer.

C. Annual Reporting Burden

Respondents: 7,998.

Responses per Respondent: 5.

Annual Responses: 39,990.

Hours per Response: 1.0.

Total Burden Hours: 39,990.

Obtaining Copies of Proposals: Requesters may obtain a copy of the information collection documents from the General Services Administration, Regulatory Secretariat Division (MVCB), 1800 F Street NW, Washington, DC 20405, telephone 202–501–4755. Please cite OMB Control No. 9000–0083, Qualification Requirements, in all correspondence.

Dated: April 8, 2019.

Janet Fry,

Director, Federal Acquisition Policy Division, Office of Governmentwide Acquisition Policy, Office of Acquisition Policy, Office of Governmentwide Policy.

[FR Doc. 2019–07268 Filed 4–11–19; 8:45 am]

BILLING CODE 6820–EP–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Healthcare Research and Quality

Supplemental Evidence and Data Request on Skin Substitutes for Treating Chronic Wounds

AGENCY: Agency for Healthcare Research and Quality (AHRQ), HHS.

ACTION: Request for supplemental evidence and data submissions.

SUMMARY: The Agency for Healthcare Research and Quality (AHRQ) is seeking scientific information submissions from the public. Scientific information is being solicited to inform our review on *Skin Substitutes for Treating Chronic Wounds,* which is currently being conducted by the AHRQ's Evidence-based Practice Centers (EPC) Program. Access to published and unpublished pertinent scientific information will improve the quality of this review.

DATES: *Submission Deadline* on or before May 13, 2019.

ADDRESSES:

Email submissions: epc@ahrq.hhs.gov.

Print submissions:

Mailing Address: Center for Evidence and Practice Improvement, Agency for Healthcare Research and Quality, ATTN: EPC SEADs Coordinator, 5600 Fishers Lane, Mail Stop 06E53A, Rockville, MD 20857

Shipping Address (FedEx, UPS, etc.): Center for Evidence and Practice Improvement, Agency for Healthcare Research and Quality, ATTN: EPC SEADs Coordinator, 5600 Fishers Lane, Mail Stop 06E77D, Rockville, MD 20857

FOR FURTHER INFORMATION CONTACT: Jenae Benns, Telephone: 301–427–1496 or Email: *epc@ahrq.hhs.gov.*

SUPPLEMENTARY INFORMATION: The Agency for Healthcare Research and Quality has commissioned the Evidence-based Practice Centers (EPC) Program to complete a review of the evidence for *Skin Substitutes for Treating Chronic Wounds.* AHRQ is conducting this systematic review pursuant to Section 902(a) of the Public Health Service Act, 42 U.S.C. 299a(a).

The EPC Program is dedicated to identifying as many studies as possible that are relevant to the questions for each of its reviews. In order to do so, we are supplementing the usual manual and electronic database searches of the literature by requesting information from the public (*e.g.,* details of studies conducted). We are looking for studies that report on *Skin Substitutes for Treating Chronic Wounds,* including those that describe adverse events. The entire research protocol, including the key questions, is also available online at: *https://www.ahrq.gov/research/findings/ta/index.html.*

This is to notify the public that the EPC Program would find the following information on Skin Substitutes for Treating Chronic Wounds helpful:

- A list of completed studies that your organization has sponsored for this indication. In the list, please *indicate whether results are available on ClinicalTrials.gov along with the ClinicalTrials.gov trial number.*
- *For completed studies that do not have results on ClinicalTrials.gov,* please provide a summary, including the following elements: Study number, study period, design, methodology, indication and diagnosis, proper use instructions, inclusion and exclusion criteria, primary and secondary outcomes, baseline characteristics, number of patients screened/eligible/enrolled/lost to follow-up/withdrawn/analyzed, effectiveness/efficacy, and safety results.
- *A list of ongoing studies that your organization has sponsored for this indication.* In the list, please provide the *ClinicalTrials.gov* trial number or, if the trial is not registered, the protocol for the study including a study number, the study period, design, methodology, indication and diagnosis, proper use instructions, inclusion and exclusion criteria, and primary and secondary outcomes.
- Description of whether the above studies constitute ALL Phase II and above clinical trials sponsored by your organization for this indication and an index outlining the relevant information in each submitted file.

Your contribution will be very beneficial to the EPC Program. Materials submitted must be publicly available or able to be made public. Materials that are considered confidential; marketing materials; study types not included in the review; or information on indications not included in the review cannot be used by the EPC Program. This is a voluntary request for information, and all costs for complying with this request must be borne by the submitter.

The draft of this review will be posted on AHRQ's EPC Program website and available for public comment for a period of 4 weeks. If you would like to be notified when the draft is posted, please sign up for the email list at: *https://www.effectivehealthcare.ahrq.gov/email-updates.*